Protocol Number:
AHOD1331
Study Name:
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (CHL) in Children and Adolescents
Age Group:
Pediatrics
Background Information:
See full details